Quintiles maintains 'outperform' rating following recent flurry of activity

By Dan Stanton contact

- Last updated on GMT

Related tags: Asia-pacific

A new Asia-Pacific market access service and the acquisition of Japanese CRO Clio Science has helped bolster Quintiles' investment desirability
A new Asia-Pacific market access service and the acquisition of Japanese CRO Clio Science has helped bolster Quintiles' investment desirability
A recent spate of activity - including the acquisition of a Japanese CRO and a secondary equity offering - has boosted Quintiles’ investment appeal, an analyst says.

The world’s largest contract research organisation (CRO) Quintiles has had a busy few weeks:

Last week it announced it has fully acquired Clio Science, a full-service CRO with a staff of 70 based in Tokyo and Osaka. Also this month, Quintiles opened a new bioanalytical lab in the Netherlands​ and, on the financial side,  secured almost $2bn (€1.8bn)​ following the completion of a refinancing programme.

“While none of these events has a major impact on our model, we have updated our estimates to reflect the flurry of activity,”​ William Blair analyst John Kreger said in a note.

“We maintain our Outperform rating on Quintiles given strong bookings and a more attractive valuation of late, and continue to view Quintiles as the most diversified way to invest in late-stage pharma outsourcing.”

Asia-Pacific market access

In its latest announcement, Quintiles is launching a new service for emerging biopharma companies in the Asia-Pacific region, based on its estimation that there are over 1,400 such firms across the region looking for help accessing the regional and global markets.

“We work with all sized companies but smaller emerging biopharma companies have a number of regulatory and access challenges and needs that need to be addressed,”​ Quintiles spokesman Jay Johnson told Outsourcing-Pharma.com.

“Other CROs do offer these services but what we did was take a look at the services that we had across our network in 13 Asia-Pacific countries and decided this new solution set would work best.”

The service includes dedicated local project leadership in the region, offering knowledge of local markets, customs and language, and accelerated patient recruitment due to the firm’s global and Asia-Pacific network.

Related news

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars